Literature DB >> 24935955

Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.

Charlene Wang1, Mohamed Abdel-Mohsen2, Matthew C Strain3, Steven M Lada3, Steven Yukl4, Leslie R Cockerham5, Christopher D Pilcher5, Frederick M Hecht5, Elizabeth Sinclair5, Teri Liegler5, Douglas D Richman3, Steven G Deeks5, Satish K Pillai2.   

Abstract

Individuals who are heterozygous for the CCR5-Δ32 mutation provide a natural model to examine the effects of reduced CCR5 expression on human immunodeficiency virus (HIV) persistence. We evaluated the HIV reservoir in 18 CCR5-Δ32 heterozygotes and 54 CCR5 wild-type individuals during suppressive antiretroviral therapy. Cell-associated HIV RNA levels (P=.035), RNA to DNA transcriptional ratios (P=.013), and frequency of detectable HIV 2-long terminal repeat circular DNA (P=.013) were significantly lower in CD4+ T cells from CCR5-Δ32 heterozygotes. Cell-associated HIV RNA was significantly correlated with CCR5 surface expression on CD4+ T cells (r2=0.136; P=.002). Our findings suggest that curative strategies should further explore manipulation of CCR5.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CCR5; HIV; HIV replication; HIV transcription; NF-κB; coreceptor; eradication; latency; reservoir; Δ32

Mesh:

Substances:

Year:  2014        PMID: 24935955      PMCID: PMC4271057          DOI: 10.1093/infdis/jiu338

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication.

Authors:  Theodore C Pierson; Tara L Kieffer; Christian T Ruff; Christopher Buck; Stephen J Gange; Robert F Siliciano
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling.

Authors:  Bing Tian; David E Nowak; Mohammad Jamaluddin; Shaofei Wang; Allan R Brasier
Journal:  J Biol Chem       Date:  2005-02-18       Impact factor: 5.157

3.  The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

Authors:  Y Huang; W A Paxton; S M Wolinsky; A U Neumann; L Zhang; T He; S Kang; D Ceradini; Z Jin; K Yazdanbakhsh; K Kunstman; D Erickson; E Dragon; N R Landau; J Phair; D D Ho; R A Koup
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

4.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Authors:  Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

5.  No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users.

Authors:  J Schinkel; M W Langendam; R A Coutinho; A Krol; M Brouwer; H Schuitemaker
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

6.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

Review 7.  Immunogenetics of HIV disease.

Authors:  Maureen P Martin; Mary Carrington
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

8.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

9.  Highly precise measurement of HIV DNA by droplet digital PCR.

Authors:  Matthew C Strain; Steven M Lada; Tiffany Luong; Steffney E Rought; Sara Gianella; Valeri H Terry; Celsa A Spina; Christopher H Woelk; Douglas D Richman
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

Review 10.  Cell-associated HIV RNA: a dynamic biomarker of viral persistence.

Authors:  Alexander O Pasternak; Vladimir V Lukashov; Ben Berkhout
Journal:  Retrovirology       Date:  2013-04-15       Impact factor: 4.602

View more
  5 in total

1.  CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Authors:  Timothy J Henrich; Emily Hanhauser; Linda J Harrison; Christine D Palmer; Marisol Romero-Tejeda; Stephanie Jost; Ronald J Bosch; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2015-10-28       Impact factor: 5.226

2.  Select host restriction factors are associated with HIV persistence during antiretroviral therapy.

Authors:  Mohamed Abdel-Mohsen; Charlene Wang; Matthew C Strain; Steven M Lada; Xutao Deng; Leslie R Cockerham; Christopher D Pilcher; Frederick M Hecht; Teri Liegler; Douglas D Richman; Steven G Deeks; Satish K Pillai
Journal:  AIDS       Date:  2015-02-20       Impact factor: 4.177

3.  People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells.

Authors:  Louise E van Eekeren; Vasiliki Matzaraki; Zhenhua Zhang; Lisa van de Wijer; Marc J T Blaauw; Marien I de Jonge; Linos Vandekerckhove; Wim Trypsteen; Leo A B Joosten; Mihai G Netea; Quirijn de Mast; Hans J P M Koenen; Yang Li; André J A M van der Ven
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

4.  Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation.

Authors:  Mohamed Abdel-Mohsen; Leonard Chavez; Ravi Tandon; Glen M Chew; Xutao Deng; Ali Danesh; Sheila Keating; Marion Lanteri; Michael L Samuels; Rebecca Hoh; Jonah B Sacha; Philip J Norris; Toshiro Niki; Cecilia M Shikuma; Mitsuomi Hirashima; Steven G Deeks; Lishomwa C Ndhlovu; Satish K Pillai
Journal:  PLoS Pathog       Date:  2016-06-02       Impact factor: 6.823

5.  Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection.

Authors:  Zhepeng Liu; Shuliang Chen; Xu Jin; Qiankun Wang; Kongxiang Yang; Chenlin Li; Qiaoqiao Xiao; Panpan Hou; Shuai Liu; Shaoshuai Wu; Wei Hou; Yong Xiong; Chunyan Kong; Xixian Zhao; Li Wu; Chunmei Li; Guihong Sun; Deyin Guo
Journal:  Cell Biosci       Date:  2017-09-09       Impact factor: 7.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.